Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal AC polysaccharide vaccine + PRP polysaccharide vaccine
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a combination vaccine containing **purified polysaccharide antigens** from Neisseria meningitidis serogroups A and C (meningococcal AC) and from *Haemophilus influenzae* type b (Hib) in the form of polyribosylribitol phosphate (PRP) polysaccharide. The antigens are not conjugated to protein carriers, making it a plain polysaccharide vaccine, not a conjugate. The vaccine induces antibody-mediated (humoral) immunity primarily through production of serogroup-specific antibodies (T-cell-independent response). Meningococcal polysaccharide vaccines are effective in older children and adults but are less immunogenic and induce limited immune memory in young children[1][2]. The PRP component is designed to induce immunity against invasive Hib disease through antibodies against the Hib capsule.
- Other names
- meningococcal A/C polysaccharide vaccine + Haemophilus influenzae type b PRP polysaccharide vaccineMenA/C + Hib PRP polysaccharide vaccine
02
Targets
PRNP (Cellular Prion Protein)NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal AC polysaccharide vaccine + PRP polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal AC polysaccharide vaccine + PRP polysaccharide vaccine.